DVAX Stock Overview
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States.
Dynavax Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$11.68|
|52 Week High||US$21.39|
|52 Week Low||US$7.26|
|1 Month Change||23.73%|
|3 Month Change||-6.41%|
|1 Year Change||40.55%|
|3 Year Change||135.01%|
|5 Year Change||106.73%|
|Change since IPO||-87.57%|
Recent News & Updates
Dynavax: Evolving Endemic Situation Adds To Its Risk
DVAX will do well as long as the coronavirus vaccine demand exists. While the urgency is somewhat abated, an evolving endemic situation may continue to need CpG 1018. If it doesn't, HEPLISAV-B alone will not save the day.
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
Dynavax Technologies Corporation ( NASDAQ:DVAX ) just reported healthy earnings but the stock price didn't move much...
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
|DVAX||US Biotechs||US Market|
Return vs Industry: DVAX exceeded the US Biotechs industry which returned -22.1% over the past year.
Return vs Market: DVAX exceeded the US Market which returned -15.1% over the past year.
|DVAX Average Weekly Movement||11.7%|
|Biotechs Industry Average Movement||12.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: DVAX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: DVAX's weekly volatility (12%) has been stable over the past year.
About the Company
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.
Dynavax Technologies Fundamentals Summary
|DVAX fundamental statistics|
Is DVAX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|DVAX income statement (TTM)|
|Cost of Revenue||US$218.95m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.82|
|Net Profit Margin||22.19%|
How did DVAX perform over the long term?See historical performance and comparison
Is Dynavax Technologies undervalued compared to its fair value and its price relative to the market?
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: DVAX ($11.68) is trading below our estimate of fair value ($20.52)
Significantly Below Fair Value: DVAX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: DVAX is good value based on its Price-To-Earnings Ratio (14.2x) compared to the US Biotechs industry average (15.4x).
PE vs Market: DVAX is good value based on its Price-To-Earnings Ratio (14.2x) compared to the US market (15.2x).
Price to Earnings Growth Ratio
PEG Ratio: DVAX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: DVAX is overvalued based on its Price-To-Book Ratio (5.1x) compared to the US Biotechs industry average (1.4x).
How is Dynavax Technologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DVAX's earnings are forecast to decline over the next 3 years (-25.3% per year).
Earnings vs Market: DVAX's earnings are forecast to decline over the next 3 years (-25.3% per year).
High Growth Earnings: DVAX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: DVAX's revenue is expected to decline over the next 3 years (-7.7% per year).
High Growth Revenue: DVAX's revenue is forecast to decline over the next 3 years (-7.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DVAX's Return on Equity is forecast to be high in 3 years time
How has Dynavax Technologies performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DVAX has high quality earnings.
Growing Profit Margin: DVAX became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: DVAX has become profitable over the past 5 years, growing earnings by 26.7% per year.
Accelerating Growth: DVAX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: DVAX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: DVAX's Return on Equity (37.8%) is considered high.
How is Dynavax Technologies's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: DVAX's short term assets ($940.5M) exceed its short term liabilities ($466.2M).
Long Term Liabilities: DVAX's short term assets ($940.5M) exceed its long term liabilities ($255.3M).
Debt to Equity History and Analysis
Debt Level: DVAX has more cash than its total debt.
Reducing Debt: Insufficient data to determine if DVAX's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: DVAX's debt is well covered by operating cash flow (111.9%).
Interest Coverage: DVAX's interest payments on its debt are well covered by EBIT (18.5x coverage).
What is Dynavax Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DVAX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DVAX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DVAX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DVAX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as DVAX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ryan Spencer (43 yo)
Mr. Ryan Spencer serves as the Chief Executive Officer and Director of Dynavax Technologies Corp. since December 16, 2019. He had been Co-President and Co-Principal Executive Officer of Dynavax Technologie...
CEO Compensation Analysis
Compensation vs Market: Ryan's total compensation ($USD4.52M) is about average for companies of similar size in the US market ($USD5.40M).
Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.
Experienced Management: DVAX's management team is considered experienced (2.2 years average tenure).
Experienced Board: DVAX's board of directors are considered experienced (3.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: DVAX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.2%.
Dynavax Technologies Corporation's employee growth, exchange listings and data sources
- Name: Dynavax Technologies Corporation
- Ticker: DVAX
- Exchange: NasdaqCM
- Founded: 1996
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$1.475b
- Shares outstanding: 126.31m
- Website: https://www.dynavax.com
Number of Employees
- Dynavax Technologies Corporation
- 2100 Powell Street
- Suite 900
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/26 00:00|
|End of Day Share Price||2022/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.